Nanoliposomal irinotecan (NCT06835387)

Name: Nanoliposomal irinotecan trial for Small Bowel Adenocarcinoma (NCT06835387)
Uploaded: 2026-10-31T21:02:59.764Z
Duration: 1 min 23 s
Description: Nanoliposomal irinotecan trial for Small Bowel Adenocarcinoma (NCT06835387). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06835387.

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors: a one-minute explainerNCT068353871 min

Nanoliposomal irinotecan trial for Small Bowel Adenocarcinoma (NCT06835387). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with unresectable metastatic small-bowel adenocarcinoma that is mismatch-repair proficient or microsatellite stable. Intestinal-type ampullary cancer qualifies. One prior FOLFOX cycle is allowed; prior irinotecan is excluded.

The idea: NALIRIFOX combines liposomal irinotecan, oxaliplatin, fluorouracil, and leucovorin. Irinotecan blocks repair of DNA breaks during copying. Intravenous treatment repeats twice per four-week cycle, for up to six cycles. Depending on response, maintenance without oxaliplatin may follow. Researchers measure tumor response.

This phase 2 study plans 36 patients. Tiago Biachi de Castria leads at Moffitt in Tampa; seven US sites recruit.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.